MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has reported a significant change in its major holdings, revealing that BlackRock, Inc. has altered its stake in the company. As of September 10, 2024, BlackRock’s total voting rights in MaxCyte have increased to 9.74%, up from the previous notification of 9.47%. This change in share ownership demonstrates BlackRock’s increased interest in the biotechnology firm and could potentially impact MaxCyte’s stock market performance.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
